Nabriva Therapeutics plc Quarterly Cost of Revenue in USD from Q3 2020 to Q2 2023

Taxonomy & unit: us-gaap: USD
Description: The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary: Nabriva Therapeutics plc quarterly/annual Cost of Revenue history and growth rate from Q3 2020 to Q2 2023.
Nabriva Therapeutics plc Cost of Revenue for the quarter ending June 30, 2023 was $9.07M, a 104% increase year-over-year.
Nabriva Therapeutics plc Cost of Revenue for the twelve months ending June 30, 2023 was $34.3M, a 98.4% increase year-over-year.
Nabriva Therapeutics plc annual Cost of Revenue for 2022 was $28.6M, a 117% increase from 2021.
Nabriva Therapeutics plc annual Cost of Revenue for 2021 was $13.1M, a 1616% increase from 2020.
Nabriva Therapeutics plc annual Cost of Revenue for 2020 was $766K, a 994% increase from 2019.

Cost of Revenue, Trailing 12 Months (USD)

Cost of Revenue, Quarterly (USD)

Cost of Revenue, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2023	$34.3M	$9.07M	+$4.62M	+104%	Apr 1, 2023	Jun 30, 2023	10-Q	2023-10-19
Q1 2023	$29.7M	$4.44M	+$1.08M	+32%	Jan 1, 2023	Mar 31, 2023	10-Q	2023-05-22
Q4 2022	$28.6M	$16.3M	+$11.1M	+210%	Oct 1, 2022	Dec 31, 2022	10-K	2023-04-17
Q3 2022	$17.5M	$4.42M	+$217K	+5.17%	Jul 1, 2022	Sep 30, 2022	10-Q	2022-11-10
Q2 2022	$17.3M	$4.46M	+$834K	+23%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-10-19
Q1 2022	$16.4M	$3.36M	+$3.3M	+5321%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-22
Q4 2021	$13.1M	$5.27M			Oct 1, 2021	Dec 31, 2021	10-K	2023-04-17
Q3 2021		$4.2M	+$4.17M	+16696%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-10
Q2 2021		$3.62M			Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-03
Q1 2021		$62K			Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-05
Q3 2020		$25K			Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-09

* An asterisk sign (*) next to the value indicates that the value is likely invalid.